Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
Recruiting · NCT06659705 · Interventional (participants receive a specific treatment) · Lead sponsor: Institut Curie
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening. In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process. All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared. Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.
Who can take part
Inclusion criteria
- Cyto/histologically proven PDAC
- Non-metastatic proven PDAC on recent (\< 1 month) CT-scan and MRI
- Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983)
- Age \> 18 years old
- Affiliation to a social security scheme
- Signed informed consent
Exclusion criteria
- Protected adults (guardianship, curatorship or safeguarding justice)
- Pregnant or breastfeeding woman
- Women of childbearing potential not using one highly effective method of contraception
Where it is running
1 location listed.
- Institut Curie -site Saint-Cloud - Saint-Cloud, France